Plain-English translation of NCT04628429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how anti-CGRP antibodies — a newer type of migraine medicine — affects the autonomic nervous system (the part of your body that controls automatic functions like heart rate and digestion) in people with episodic or chronic migraines. This study compares how the medication works in migraine patients versus healthy volunteers, and measures changes in nerve function before and after treatment.
Current migraine prevention medications were not originally designed for migraines and often cause unwanted side effects like fatigue, depression, and sleep problems. This medication represents a more targeted approach, and researchers want to understand exactly how it helps the body and whether it affects the nervous system in ways that might explain its benefits.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as prescribed by your doctor and undergo standardized tests to measure your nervous system's function — likely including heart rate monitoring, blood pressure checks, and other autonomic assessments. These tests would be performed before starting the medication and again during treatment to see how the medicine affects your body's automatic nervous system responses. The study involves recruiting 120 participants total, including people with episodic migraines, people with chronic migraines, and healthy volunteers for comparison.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Austria